Abstract
Cancer therapy is facing the big challenge of destroying selectively tumour cells without harming the normal tissues. Chemotherapy was trying from the beginning to kill malignant cells because of their proliferative activity since normal cells are in general quiescent. Meanwhile side effects were produced due to the destruction of some normal cells that need regular proliferation. The discovery of biomarkers led to the identification of molecular targets within tumour cells in order to kill them selectively. Chemistry followed the progress of biomarkers biotechnology by the production of target specific antagonists which were the subject of many patents. Meanwhile novel problems of tumour resistance appeared and made the battle against cancer a non stop development of new strategies and new weapons. As a consequence, paralleled activities of patenting biomarkers and chemical antagonists are continuously generated. The offer of chemistry does not actually limit the efficiency of Targeted therapy but the identification of biomarkers is still missing the exclusive specificity to tumour cells.
Keywords: Drug approval, neoplasms, cells, drug therapy, combination, drug targeting, efficiency, antagonists and inhibitors, mutation, patients, cell proliferation, proto-oncogene, drug resistance, molecular targeted therapy, united states food and drug administration, screening, target, anti-angiogenic agents
Recent Patents on Biotechnology
Title: The Offer of Chemistry to Targeted Therapy in Cancer
Volume: 5 Issue: 3
Author(s): Ikram Jemel, Karim Jellali, Jihene Elloumi and Sami Aifa
Affiliation:
Keywords: Drug approval, neoplasms, cells, drug therapy, combination, drug targeting, efficiency, antagonists and inhibitors, mutation, patients, cell proliferation, proto-oncogene, drug resistance, molecular targeted therapy, united states food and drug administration, screening, target, anti-angiogenic agents
Abstract: Cancer therapy is facing the big challenge of destroying selectively tumour cells without harming the normal tissues. Chemotherapy was trying from the beginning to kill malignant cells because of their proliferative activity since normal cells are in general quiescent. Meanwhile side effects were produced due to the destruction of some normal cells that need regular proliferation. The discovery of biomarkers led to the identification of molecular targets within tumour cells in order to kill them selectively. Chemistry followed the progress of biomarkers biotechnology by the production of target specific antagonists which were the subject of many patents. Meanwhile novel problems of tumour resistance appeared and made the battle against cancer a non stop development of new strategies and new weapons. As a consequence, paralleled activities of patenting biomarkers and chemical antagonists are continuously generated. The offer of chemistry does not actually limit the efficiency of Targeted therapy but the identification of biomarkers is still missing the exclusive specificity to tumour cells.
Export Options
About this article
Cite this article as:
Jemel Ikram, Jellali Karim, Elloumi Jihene and Aifa Sami, The Offer of Chemistry to Targeted Therapy in Cancer, Recent Patents on Biotechnology 2011; 5 (3) . https://dx.doi.org/10.2174/187220811797579079
DOI https://dx.doi.org/10.2174/187220811797579079 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
β-Glucans: Old Molecules with Newly Discovered Immunological Activities
Drug Design Reviews - Online (Discontinued) Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design Derivatives of IL-16 to Modulate Airway Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antitumor Activity of Polysaccharides: An Overview
Current Drug Targets Role of ABC Transporters in Veterinary Drug Research and Parasite Resistance
Current Drug Delivery Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Rationale Design of GPER Ligands
Current Medicinal Chemistry Helenalin - A Sesquiterpene Lactone with Multidirectional Activity
Current Drug Targets Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Current Cancer Drug Targets Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry Anti-MDR Effects of Quercetin and its Nanoemulsion in Multidrug-Resistant Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry A QSAR Study on Some Series of Anticancer Tyrosine Kinase Inhibitors
Medicinal Chemistry Overview of the Role of Annexin 1 in the Innate and Adaptive Immune Response
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism